(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Hypercholesterolemia D006937 91 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperlipoproteinemias D006951 15 associated lipids
Hyperlipoproteinemia Type III D006952 4 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Keloid D007627 12 associated lipids
Leukemia D007938 74 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
Hilgers LA et al. A novel non-mineral oil-based adjuvant. I. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in laboratory animals. 1994 Vaccine pmid:8085385
Hilgers LA et al. A novel non-mineral oil-based adjuvant. II. Efficacy of a synthetic sulfolipopolysaccharide in a squalane-in-water emulsion in pigs. 1994 Vaccine pmid:8085386
Heineman TC et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. 1999 Vaccine pmid:10438046
De Donato S et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. 1999 Vaccine pmid:10462245
Black S et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. 2010 Vaccine pmid:20813217
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
de Bruijn I et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. 2007 Vaccine pmid:18063446
Schultze V et al. Safety of MF59 adjuvant. 2008 Vaccine pmid:18462843
Tetsutani K and Ishii KJ Adjuvants in influenza vaccines. 2012 Vaccine pmid:23084848
Poder A et al. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. 2014 Vaccine pmid:24252703